<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04439890</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-03-III-01</org_study_id>
    <nct_id>NCT04439890</nct_id>
  </id_info>
  <brief_title>A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter Phase III Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, multicenter phase III clinical study to evaluate efficacy&#xD;
      and safety of anlotinib hydrochloride capsule combined with chemotherapy versus placebo&#xD;
      combined with chemotherapy as first-line treatment in subjects with advanced non-squamous&#xD;
      cell non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) assessed by Independent Review Committee (IRC)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR) based on IRC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease of Response (DOR)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">369</enrollment>
  <condition>Advanced Non-squamous Cell Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Anlotinib hydrochloride capsule + chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib hydrochloride capsule</intervention_name>
    <description>Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)</description>
    <arm_group_label>Anlotinib hydrochloride capsule + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin injection</intervention_name>
    <description>Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.</description>
    <arm_group_label>Anlotinib hydrochloride capsule + chemotherapy</arm_group_label>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed disodium f Injection</intervention_name>
    <description>Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.</description>
    <arm_group_label>Anlotinib hydrochloride capsule + chemotherapy</arm_group_label>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Local advanced (stage IIIB / ⅢC), metastatic or recurrent (stage IV) non-squamous&#xD;
             cell non-small cell lung cancer, has at least one measurable lesion.&#xD;
&#xD;
             2. EGFR, ALK, and ROS1 test results are negative. 3. Eastern Cooperative Oncology&#xD;
             Group (ECOG) performance status of 0 or 1, life expectancy≥ 12 weeks.&#xD;
&#xD;
             4. Has not received systemic anti-tumor treatment for advanced disease. 5.Adequate&#xD;
             organ system function. 6. Male or female subjects should agree to use an adequate&#xD;
             method of contraception starting with the first dose of study therapy through 6 months&#xD;
             after the last dose of study (such as intrauterine devices , contraceptives or&#xD;
             condoms) ; No pregnant or breastfeeding women, and a negative pregnancy test are&#xD;
             received within 7 days before the randomization.&#xD;
&#xD;
             7. Understood and signed an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Other histopathological types of non-small cell lung cancer. 2.Has received VEGF&#xD;
             pathway targeted therapy including anlotinib and bevacizumab.&#xD;
&#xD;
             3. Has multiple factors affecting oral medication. 4. Has symptomatic brain&#xD;
             metastases. 5. Has uncontrollable pleural effusion, pericardial effusion, or ascites&#xD;
             requiring recurrent drainage procedures.&#xD;
&#xD;
             6. Has adverse events caused by previous therapy except alopecia that did not recover&#xD;
             to ≤grade 1.&#xD;
&#xD;
             7. Has any severe and / or uncontrolled diseases. 8. Has any bleeding symptoms or&#xD;
             treated with anticoagulants or vitamin K antagonists.&#xD;
&#xD;
             9.Has received surgery, or unhealed wounds within 4 weeks before the first&#xD;
             administration.&#xD;
&#xD;
             10. Has hemoptysis within 28 days before randomization. 11. Imaging (CT or MRI) shows&#xD;
             that tumor invades large blood vessels or the boundary with blood vessels is unclear.&#xD;
&#xD;
             12. Has arterial or venous thromboembolic events occurred within 6 months, such as&#xD;
             cerebrovascular accident including transient ischemic attack, deep vein thrombosis and&#xD;
             pulmonary embolism.&#xD;
&#xD;
             13. Has psychotropic substances abuse or a mental disorder. 14. Have a history of&#xD;
             immunodeficiency. 15. Has received allogeneic organ transplantation, hematopoietic&#xD;
             stem cell transplantation or bone marrow transplantation.&#xD;
&#xD;
             16. Has other malignancy. 17.Has participated in other anticancer drug clinical trials&#xD;
             within 4 weeks. 18.According to the judgement of the researchers, there are other&#xD;
             factors that may lead to the termination of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Zhao, Doctor</last_name>
      <email>dy61321157@163.com</email>
    </contact>
    <investigator>
      <last_name>Hui Zhao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anhui Chest Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuhong Min, Doctor</last_name>
      <email>13855179548‬@163.com</email>
    </contact>
    <investigator>
      <last_name>Xuhong Min, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yijishan Hospital of Wannan Medical College</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <zip>242400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiwei Lu, Doctor</last_name>
      <email>sduzhiwei@sina.com</email>
    </contact>
    <investigator>
      <last_name>Zhiwei Lu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chest Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baolan Li, Doctor</last_name>
      <email>libaolan1109@163.com</email>
    </contact>
    <investigator>
      <last_name>Baolan Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baoshan Cao, Doctor</last_name>
      <email>caobaoshan0711@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Baoshan Cao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sixth Medical Center of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhihai Han, Doctor</last_name>
      <email>hanzhihai@souhu.com</email>
    </contact>
    <investigator>
      <last_name>Zhihai Han, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital of Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Zhang, Doctor</last_name>
      <email>steven9130@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yi Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang, Doctor</last_name>
      <email>zhanglipumch@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Li Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>431338</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Chen, Doctor</last_name>
      <email>417335669@qq.com</email>
    </contact>
    <investigator>
      <last_name>Hong Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Chinese PLA Army Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>431338</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi Xu, Doctor</last_name>
      <email>xu_zhi999@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhi Xu, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu Zhuang, Doctor</last_name>
      <email>zhuangwu2008@126.com</email>
    </contact>
    <investigator>
      <last_name>Wu Zhuang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongmei Yue, Doctor</last_name>
      <email>13893265368@163.com</email>
    </contact>
    <investigator>
      <last_name>Hongmei Yue, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gansu Wuwei Tumor Hospital</name>
      <address>
        <city>Wuwei</city>
        <state>Gansu</state>
        <zip>733000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengguo Li, Doctor</last_name>
      <email>lizhengguo190@sina.com</email>
    </contact>
    <investigator>
      <last_name>Zhengguo Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhong Lin, Doctor</last_name>
      <email>linzhong123@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhong Lin, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangdong Pharmaceutical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Ding, Doctor</last_name>
      <email>dy61321157@163.com</email>
    </contact>
    <investigator>
      <last_name>Ying Ding, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510289</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minhui Wang, Doctor</last_name>
      <email>wmingh@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Minhui Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meizhou People's Hospital</name>
      <address>
        <city>Meizhou</city>
        <state>Guangdong</state>
        <zip>514798</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guowu Wu, Doctor</last_name>
      <email>wwwflay@126.com</email>
    </contact>
    <investigator>
      <last_name>Guowu Wu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qitao Yu, Doctor</last_name>
      <email>yqt178@163.com</email>
    </contact>
    <investigator>
      <last_name>Qitao Yu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming He, Doctor</last_name>
      <email>heming6699@sina.com</email>
    </contact>
    <investigator>
      <last_name>Ming He, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xingtai People's Hospital</name>
      <address>
        <city>Xingtai</city>
        <state>Hebei</state>
        <zip>540000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Guo, Doctor</last_name>
      <email>guojun_868@sina.com</email>
    </contact>
    <investigator>
      <last_name>Jun Guo, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Yu, Doctor</last_name>
      <email>gpyuyan@163.com</email>
    </contact>
    <investigator>
      <last_name>Yan Yu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanzhen Guo, Doctor</last_name>
      <email>guoyanzhen177@163.com</email>
    </contact>
    <investigator>
      <last_name>Yanzhen Guo, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinxiang Medical College</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>455001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongrui Niu, Doctor</last_name>
      <email>1163458431@qq.com</email>
    </contact>
    <investigator>
      <last_name>Hongrui Niu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>475000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanqiu Zhao, Doctor</last_name>
      <email>13938252350@163.com</email>
    </contact>
    <investigator>
      <last_name>Yanqiu Zhao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huazhong University of Science Tongji Hospital, Tongji Medical College</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Chen, Doctor</last_name>
      <email>18678766862@163.com</email>
    </contact>
    <investigator>
      <last_name>Yuan Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengping Hu, Doctor</last_name>
      <email>huchengp@126.com</email>
    </contact>
    <investigator>
      <last_name>Chengping Hu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>425001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Chen, Doctor</last_name>
      <email>cjh_1000@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianhua Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changzhou Second People's Hospital</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingxia Yang, Doctor</last_name>
      <email>cougermx@126.com</email>
    </contact>
    <investigator>
      <last_name>Mingxia Yang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lianyungang First People's Hospital</name>
      <address>
        <city>Lianyungang</city>
        <state>Jiangsu</state>
        <zip>222001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiashu Li, Doctor</last_name>
      <email>lissm1118@sina.com</email>
    </contact>
    <investigator>
      <last_name>Jiashu Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Nantong University</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226691</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Feng, Doctor</last_name>
      <email>jfeng68@126.com</email>
    </contact>
    <investigator>
      <last_name>Jian Feng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuping Du, Doctor</last_name>
      <email>1422363662@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xiuping Du, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Subei People's Hospital</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>211400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingxiang Xu, Doctor</last_name>
      <email>Xuxxu63@sina.com</email>
    </contact>
    <investigator>
      <last_name>Xingxiang Xu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhang, Doctor</last_name>
      <email>13707089183@163.com</email>
    </contact>
    <investigator>
      <last_name>Wei Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yarong Li, Doctor</last_name>
      <email>Doctor.lyr@163.com</email>
    </contact>
    <investigator>
      <last_name>Yarong Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Zhang, Doctor</last_name>
      <email>zydley@163.com</email>
    </contact>
    <investigator>
      <last_name>Yang Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunpeng Liu, Doctor</last_name>
      <email>cmu_trial@163.com</email>
    </contact>
    <investigator>
      <last_name>Yunpeng Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weijun Bai, Doctor</last_name>
      <email>18900917878@163.com</email>
    </contact>
    <investigator>
      <last_name>Weijun Bai, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Hohhot</city>
        <state>Neimenggu</state>
        <zip>010010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuhua Fu, Doctor</last_name>
      <email>1499521269@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xiuhua Fu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ningxia Medical University General Hospital</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhou, Doctor</last_name>
      <email>zhw0306@126.com</email>
    </contact>
    <investigator>
      <last_name>Wei Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuwen Wang, Doctor</last_name>
      <email>wangxiuwen@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Xiuwen Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jining Medical University</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <zip>272000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shucheng Ye, Doctor</last_name>
      <email>18678766862@163.com</email>
    </contact>
    <investigator>
      <last_name>Shucheng Ye, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linyi Cancer Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>277739</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Shi, Doctor</last_name>
      <email>lyzlyygcp@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianhua Shi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tengzhou Central People's Hospital</name>
      <address>
        <city>Tengzhou</city>
        <state>Shandong</state>
        <zip>277500</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Li, Doctor</last_name>
      <email>lilingtz@163.com</email>
    </contact>
    <investigator>
      <last_name>Lin Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jialei Wang, Doctor</last_name>
      <email>luwangjialei@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jialei Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baohui Han, Doctor</last_name>
      <phone>021-22200000-3138</phone>
    </contact>
    <investigator>
      <last_name>Baohui Han, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linfen Central Hospital</name>
      <address>
        <city>Linfen</city>
        <state>Shanxi</state>
        <zip>314000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanli Li, Doctor</last_name>
      <email>1270005400@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yanli Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>300409</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shouan Ren, Doctor</last_name>
      <email>renshouan@163.com</email>
    </contact>
    <investigator>
      <last_name>Shouan Ren, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital, The Fourth Military Medical University of PLA</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Zhang, Doctor</last_name>
      <email>zhangft@fmmu.edu.com</email>
    </contact>
    <investigator>
      <last_name>Tao Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>721001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manxiang Li, Doctor</last_name>
      <email>manxiangli@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Manxiang Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dazhou Central Hospital</name>
      <address>
        <city>Dazhou</city>
        <state>Sichuan</state>
        <zip>635000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fudao Wu, Doctor</last_name>
      <email>wfde@163.com</email>
    </contact>
    <investigator>
      <last_name>Fudao Wu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Chest Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xun Zhang, Doctor</last_name>
      <email>zhangxun69@163.com</email>
    </contact>
    <investigator>
      <last_name>Xun Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diansheng Zhong, Doctor</last_name>
      <email>zhongdsh@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Diansheng Zhong, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dingzhi Huang, Doctor</last_name>
      <email>dingzhih72@163.com</email>
    </contact>
    <investigator>
      <last_name>Dingzhi Huang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhigang Han, Doctor</last_name>
      <email>1378213986@qq.com</email>
    </contact>
    <investigator>
      <last_name>Zhigang Han, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaofeng Li, Doctor</last_name>
      <email>ligaofenghl@126.com</email>
    </contact>
    <investigator>
      <last_name>Gaofeng Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinmin Yu, Doctor</last_name>
      <email>yuxm@zjcc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Xinmin Yu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianying Zhou, Doctor</last_name>
      <email>Drzjy@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianying Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Li, Doctor</last_name>
      <email>liwenzjhz0408@163.com</email>
    </contact>
    <investigator>
      <last_name>Wen Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruian People's Hospital</name>
      <address>
        <city>Ruian</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zongxiao Shangguan, Doctor</last_name>
      <email>sangxao0707@163.com</email>
    </contact>
    <investigator>
      <last_name>Zongxiao Shangguan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04439890
org study id: ALTN-03-III-01
nct id: NCT04439890
lead sponsor: 
is fda regulated drug: No
is fda regulated device: No
This is a randomized, double-blind, multicenter phase III clinical study to evaluate efficacy
      and safety of anlotinib hydrochloride capsule combined with chemotherapy versus placebo
      combined with chemotherapy as first-line treatment in subjects with advanced non-squamous
      cell non-small cell lung cancer.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Progression free survival (PFS)
time frame: up to 48 weeks
description: PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.
measure: Overall response rate (ORR) assessed by Independent Review Committee (IRC)
time frame: up to 48 weeks
description: Percentage of subjects achieving complete response (CR) and partial response (PR) based on IRC.
measure: Overall survival (OS)
time frame: up to 48 weeks
description: OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.
measure: Disease control rate（DCR）
time frame: up to 48 weeks
description: Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).
measure: Disease of Response (DOR)
time frame: up to 48 weeks
description: DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.
arm group label: Anlotinib hydrochloride capsule + chemotherapy
arm group type: Experimental
description: Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
arm group label: Placebo + chemotherapy
arm group type: Placebo Comparator
description: Placebo given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
intervention type: Drug
intervention name: Anlotinib hydrochloride capsule
description: Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
arm group label: Anlotinib hydrochloride capsule + chemotherapy
intervention type: Drug
intervention name: Carboplatin injection
description: Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.
arm group label: Anlotinib hydrochloride capsule + chemotherapy
arm group label: Placebo + chemotherapy
intervention type: Drug
intervention name: Pemetrexed disodium f Injection
description: Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.
arm group label: Anlotinib hydrochloride capsule + chemotherapy
arm group label: Placebo + chemotherapy
intervention type: Drug
intervention name: Placebo
description: Placebo
arm group label: Placebo + chemotherapy
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: No
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
country: China
responsible party type: Sponsor
mesh term: Lung Neoplasms
mesh term: Carcinoma, Non-Small-Cell Lung
mesh term: Carboplatin
mesh term: Pemetrexed